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Introduction 
Alzheimer’s disease is a common neurodegenerative 
disease worldwide.1,2 The most important cause mentioned 
was the accumulation of beta-amyloid (Aβ) fibril in the 
central nervous system (CNS).3 Actually disruption in Aβ 
homeostasis can lead to the accumulation of Aβ fibrils as 
plaques in the brain.4,5 These plaques can be detected by 
microglia receptors and finally activate signal cascades into 
microglia that lead to the release of inflammatory factors 
from microglia.6,7 So, in brain of patients with Alzheimer’s 
disease, there is a widespread neuroinflammation that 
can lead to neuronal apoptosis and brain atrophy.8 The 
deposition of Aβ protein is a prominent pathological 
hallmark of brains affected by Alzheimer’s disease. For 
this reason, the inhibition of Aβ production, prevention 
of Aβ fibril formation and accumulation, destabilization 
of pre-formed Aβ are considered as attractive therapeutic 
methods for the treatment of Alzheimer’s disease.9,10 
Many animal and clinical studies showed that curcumin 
as the main constituent of turmeric spice is an effective 
ingredient in reducing Aβ plaques in the brain models of 
Alzheimer’s disease.11,12 Curcumin is well-known as an 
anti-inflammation and anti-oxidant ingredient.13 It is a 
lipophilic compound that can easily cross the blood-brain 
barrier and affect Aβ plaque.13,14 It can destabilize the Aβ 
fibrils and prevent the accumulation of Aβ polymer.15,16 
Many animal studies indicated that curcumin could alter 
Aβ metabolism in Alzheimer animal models and improve 
cognition and spatial memory.17-19 But in clinical studies 
there is controversial results about its effects on Aβ 
clearance and metabolism.20,21 For this purpose, we aimed 
to review the studies which have been done in this area on 
the effects of curcumin on Aβ 1-40 plasma level in clinical 
studies to find how curcumin affects Aβ metabolism. 
Methods 
Search Strategy
We performed a systematic review and meta-analysis 
on three randomized clinical trial (RCTs) and one 
pilot study that assessed the effect of curcumin on Aβ 
plasma level in Alzheimer’s disease. For this purpose, we 
searched PubMed and Scopus databases up to December 
2020, using the following search terms: (curcumin OR 
diferuloylmethane OR curcuminoids OR turmeric 
OR “Indian saffron”) AND (“Alzheimer disease” OR 
“Alzheimer’s disease” OR “Alzheimer Syndrome” OR 
“Senile Dementia”) AND (amyloid OR “Beta amyloid” 
OR Aβ) AND (Intervention OR “controlled trial” OR 
randomized OR random OR randomly OR placebo OR 
“clinical trial” OR trial OR “randomized controlled trial” 
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OR “randomized clinical trial”). There was no restriction 
for time or published language. In addition, the reference 
list of similar articles were screened to avoid missing any 
data. Duplicate articles were removed from the reference 
list after searching. 
Inclusion Criteria
Studies with the following characteristics were included in 
the study: (1) Studies investigating the effects of curcumin 
on Aβ plasma level in Alzheimer’s disease or aged people 
with dementia, (2) Studies that reported mean ± SD for 
Aβ, or any other effect sizes from which the calculation 
of mean ± SD was possible, (3) Only studies that had 
placebo and intervention groups were selected and the 
only difference between the two groups was curcumin 
regime. 
Exclusion Criteria
In this meta-analysis, we did not enter letter-to-the-
editors, comments, short communications, reviews, 
meta-analyses and animal studies. In our initial search we 
found 408 articles in PubMed and Scopus. 64 studies were 
removed because of duplication. In addition, from 344 
articles, 337 studies were removed from our study after 
screening the full text. Only three studies were eligible to 
enter our study (Figure 1). 
Data Extraction
Data were collected in Excel and included the author’s 
name, year of publication, place of Aβ measurement, 
number, sex and mean age of the participant in each 
group, sample size, duration of treatment with curcumin 
or placebo, study design, dosage of curcumin, methods 
of measuring outcomes and finally mean ± SD changes 
of the desired variables. Data were double checked after 
extraction. Our Aβ data were converted to pg/mL. Finally, 
in studies that reported data in graphical figures, data 
were extracted using GetData Graph Digitizer 2.24 from 
figures.22 Summary of our data is shown in Table 1.
Quality Assessment
Each study was assessed for quality assessment of risk of 
bias based on the Cochrane risk of bias assessment tool.23 
The quality of each of study was screened by two reviewers 
for the following items: (1) Random sequence generation, 
(2) Allocation concealment, 93) Selective reporting, (4) 
Blinding of participants and personnel, 95) Incomplete 
outcome data, (6) Other sources of bias. Based on the 
Cochrane handbook, the methods of the studies were 
ranked as low (L), or high risk of bias (H) or unclear (U) 
for each field of bias assessment (Table 2). 
Statistical Analysis
Mean change of Aβ 1-40 plasma level was used to 
calculate effect size. Statistical analysis was performed by 
STATA, version 13.0 (Stata Corp LP, College Station, TX, 
USA). We used random effect model for inverse variance. 
To determine heterogeneity, we used Inconsistency (I2). I2 
>50% was significant for heterogeneity. The estimates of 
effect sizes were expressed as weighted mean difference 
(WMD) and 95% confidence interval (CI).
Results
Systematic Review Findings
The summery of the characteristics of the three RCTs 
included in the current systematic review and meta-
analysis are illustrated in Table 1. The studies were 
performed in 2008 and 2012. In total 213 participants 
were analyzed in these studies. The sample size of studies 
ranged from 8 to 19 participants. Two studies were from 
the United States24,25 and one study from Hong Kong.20 
Two studies had a randomized parallel clinical trial 
design24,25 and one was pilot study.20 All studies included 
both sexes. In all studies there were control or placebo 
group and intervention group. In one study curcumin 
was administrated to healthy elderly25 and in the other 
two participants had Alzheimer’s disease, confirmed by 
clinical symptoms.
 In Ringman and colleagues’ study in 201224 and in 
Baum and colleagues’ study in 2008,20 different curcumin 
dosage and duration of regime was used,; so each regime 
was considered as an independent study. The dosage of 
curcumin varied from 80 mg/d to 4 g/d and the duration 
of intervention ranged from four weeks to 6 months. 
Mean (SD) age of the participants ranged from 47 (5) to 
77.8 (7.7) years. No study had a high-quality based on 
Cochrane risk of bias assessment tool. One study has a 
moderate quality which in which one or more domains 
had an unclear risk of bias.24 The other two studies had 
a low quality since they had a high risk of bias for three 
or more domains (Table 2). In Ringman and colleagues’ 
study,24 after 24 weeks of treatment with curcumin, Aβ 
level decreased in both placebo and Alzheimer groups 
for both doses of 2 g/d and 4 g/d. Also in DiSilvestro and 
colleagues’ study 25 on healthy elderly, Aβ plasma level in 
the placebo group did not change after four weeks but in Figure 1. Flow Diagram of Study Selection.
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the curcumin group, Aβ level decreased. In Baum and 
colleagues’ study20 the Aβ level in intervention groups 
with different duration of curcumin regime (1 and 6 
months) increased significantly after 1 month. In the 
placebo group, the level of Aβ decreased after 1 month but 
then after 1 to 6 months, there was no significant change 
in Aβ levels in both groups.
Meta-analysis Finding 
Overall, three studies with total population of 213 adults 
were analyzed for the effect of curcumin on Aβ plasma 
level. Our meta-analysis showed that curcumin had 
no significant effect on Aβ level in these three studies 
(WMD: 5.3, 95% CI: 0.78-9.97). There is no significant 
heterogeneity between the studies (I2= 6.6%, P = 0.369). 
Also, we did subgroup analysis for healthy conditions and 
there was no significant change in serum IL-10 levels in 
in the two methods of measurement (WMD: -0.10, 95% 
CI:-0.44 -0.24, I2=0.000%, P = 0.495, Figure 2). 
Discussion
Curcumin is a low molecular weight molecule and 
lipophilic compound that can easily cross the blood-
brain barrier.26 Curcumin has many proinflammatory 
effects and able to neutralize many toxicity factors on 
many organs. Nowadays, curcumin was known as an 
anti-cancer genic compound.27 Recent animal studies also 
support the hypothesis that curcumin is beneficial for 
cognitive disorders.28-30 Also studies have suggested that 
dietary curcumin was associated with better cognitive 
function and lower prevalence of dementia.30,31 Another 
study showed that free curcumin could reduce amyloid 
plaque burden and insoluble Aβ peptide in the serum,32 
But in clinical studies there is controversial results about 
the effects of curcumin on dementia diseases. Our results 
from meta-analysis showed that there was no significant 
decrease of Aβ on Alzheimer’s disease in overall results 
of clinical studies. In Ringman and colleagues’ study,24 
the percent of Aβ decrease was not big. It may be the 
decrease could become larger with a longer intervention. 
Also in DiSilvestro and colleagues’ study25 there was 
no clinical or biochemical evidence of efficacy against 
Alzheimer’s disease and Aβ serum level did not change in 
the intervention group compared with the placebo group. 
In Baum and colleagues’ study20 serum Aβ-40 tended 
to rise in the intervention group; possibly, it may show 
the ability of curcumin to disaggregate Aβ deposits in 
the brain, releasing Aβ for circulation and disposal. The 
variety of severe forms of the disease in patients, duration 
from onset of the disease, duration of regime and dose of 
curcumin are important factors that can affect the results. 
If these factors are equalized between patients, the results 
will be more reliable. These factors are very important 
in the final results of the systematic review and meta-
analysis.
Conclusion 
Based on available data in our systematic review and 
meta-analysis, there was no evidence about the effects of 
curcumin to change the Aβ-40 serum level. For further 
investigation of the effect of curcumin on serum Aβ level, 
more clinical trials are needed.




























Ringman et al/ 
2012
9 11 R/P USA Both 76.7±5.6 70.2±12.4 2 g/d 24 weeks Alzheimer
Ringman et 
al/2012
10 11 R/P USA Both 75.3±6.9 70.2±12.4 4 g/d 24 weeks Alzheimer
DiSilvestro et 
al/2012
19 19 R/P USA Both 47±5 48±6 80 mg/d 4 weeks Healthy
Baum et 
al/2008
11 8 Pilot study Hong Kong Both 73.4±6.6 77.8±7.7 4 g/d 6 months Alzheimer
Baum et 
al/2008
8 8 Pilot study Hong Kong Both 69±10.9 77.8±7.7 1 g/d 1 month Alzheimer
Table 2. Assessment of Risk of Bias of Each Included Study















Ringman et al/2012 L L L L Not clear L L
DiSilvestro et al/2012 L H L H Not clear L L
Baum et al/2008 L L L Not clear Not clear H L
H, high risk ; L, low risk
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